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Neonatal sepsis remains a significant cause of morbidity and mortality especially in the
preterm infant population. The ability to promptly and accurately diagnose neonatal
sepsis based on clinical evaluation and laboratory blood tests remains challenging.
Advances in high-throughput molecular technologies have increased investigations into
the utility of transcriptomic, proteomic and metabolomic approaches as diagnostic tools
for neonatal sepsis. A systems-level understanding of neonatal sepsis, obtained by using
omics-based technologies (at the transcriptome, proteome or metabolome level), may
lead to new diagnostic tools for neonatal sepsis. In particular, recent omic-based studies
have identified distinct transcriptional signatures and metabolic or proteomic biomarkers
associated with sepsis. Despite the emerging need for a systems biology approach,
future studies have to address the challenges of integrating multi-omic data with
laboratory and clinical meta-data in order to translate outcomes into precision medicine
for neonatal sepsis. Omics-based analytical approaches may advance diagnostic tools
for neonatal sepsis. More research is needed to validate the recent systems biology
findings in order to integrate multi-dimensional data (clinical, laboratory and multi-omic)
for future translation into precision medicine for neonatal sepsis. This review will discuss
the possible applications of omics-based analyses for identification of new biomarkers
and diagnostic signatures for neonatal sepsis, focusing on the immune-compromised
preterm infant and considerations for clinical translation.
Keywords: systems biology, diagnosis, infection, neonate, sepsis, preterm infant
INTRODUCTION
Neonatal sepsis, a bacterial bloodstream infection associated with inflammation and life-
threatening organ dysfunction, is classified as early-onset sepsis (EOS, <72 h after birth) or
late-onset sepsis (LOS, >72 h) (Bateman and Seed, 2010). Prompt and accurate diagnosis
based on clinical and laboratory findings remains challenging. The complex and dynamic
disease pathophysiology often results in clinical signs that are subtle, non-specific and overlap
with non-infectious conditions (Camacho-Gonzalez et al., 2013). Consequently, there is no
consensus definition for neonatal sepsis (Wynn, 2016). Further, the current “gold standard” test,
microbiological culture, lacks sensitivity and has slow turnaround times (24–48 h). Adjunct tests
such as hematological indices and inflammatory markers either have poor sensitivity and specificity
or require serial measurements (Delanghe and Speeckaert, 2015). Simple, rapid and accurate
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diagnostic tests that can guide treatment of septic infants are
urgently needed (Dong and Speer, 2015). Markers with high
negative predictive value may allow empiric antibiotic treatment
of uninfected infants to be withheld and reduce unnecessary
antibiotic exposure associated with increased adverse short- and
long-term outcomes (Kuppala et al., 2011; Arboleya et al., 2015).
Neonatal sepsis pathophysiology involves multiple organ
systems; highlighting the need for a systems biology approach
to capture the complex interactions between biological systems
during disease (Smith et al., 2014; Alyass et al., 2015). Advances
in genomics, transcriptomics, proteomics and metabolomics
inform us of the genetic predispositions to sepsis; transcriptional
changes in host responses during sepsis; protein expression
altered by sepsis; and metabolites produced as a result of sepsis
(Fanos et al., 2013). Integrating findings from these tools into
our understanding of disease pathophysiology will enable future
translation into precision medicine, where patients are identified
and treated based on genetic, cellular and molecular markers that
relate to the underlying causes of their disease instead of common
phenotypic signs of sepsis (Flores et al., 2013; van Karnebeek
et al., 2018).
This review discusses the potential of current “omics”
approaches to characterize sepsis pathophysiology and allow the
discovery of new biomarkers and neonatal sepsis signatures.
The necessary considerations for translating these omics-based
approaches from bench-to-bedside are also considered.
Transcriptomics of the Host Response to
Sepsis
Changes in hematological markers during bacterial infections,
such as in immature-to-total neutrophil ratios and white blood
cell (WBC) counts, have been used for decades as adjunct tests
for neonatal sepsis diagnosis. However, the clinical utility of tests
remains limited by wide ranges of specificity (31–100%) and
sensitivity (17–90%), especially early in sepsis onset, and by the
considerable influence of common variables such as gestational
and postnatal age (Schmutz et al., 2008; Chirico and Loda, 2011;
Polin, 2012; Sharma et al., 2017).
The introduction of microarrays and next-generation
sequencing (NGS) technologies, particularly RNA-Sequencing
(RNA-Seq), has transformed our ability to monitor gene-
expression changes occurring at cellular level during sepsis.
Transcriptional profiling allows simultaneous measurement of
expression levels of thousands of genes, where differentially
expressed genes associated with sepsis could lead to the discovery
of novel cell-specific gene signatures for early and accurate
diagnosis of septic infants. Additionally, visualization of gene
interaction networks and identification of enriched pathways
associated with disease could improve our understanding of the
relationship between innate, adaptive and metabolic responses
during neonatal sepsis (Chaussabel et al., 2010; Skibsted et al.,
2013; Smith et al., 2014; Xia et al., 2015). This section focuses
on transcriptomic sepsis studies in the neonatal population
(Table 1).
Smith et al. analyzed blood samples from preterm and term
infants taken when investigated for suspected infection using
microarray. The study identified a 52-gene network comprising
of genes from innate, adaptive and metabolic pathways that
could distinguish bacterial infections from uninfected infants
with 98% accuracy. This combined immune-metabolic network
performed better compared to individual gene sets (65–84%)
(Smith et al., 2014). Cernada et al showed that microarray-
based gene expression profiling could discriminate between very
low birth-weight infants with bacterial sepsis and controls, with
good overall sensitivity (100%) but lower specificity (68%). The
differences observed between septic and non-septic controls were
associated with 554 differentially expressed genes mainly linked
to tumor necrosis factor and cytokine signaling (Cernada et al.,
2014). A microarray-based study by Wynn et al. demonstrated
that infants with EOS or LOS had different transcriptomes to
non-septic infants. However, early and late septic responses
differed significantly and were associated with postnatal age at
the time of sepsis. These findings underscore the importance of
controlling for postnatal age in neonatal sepsis transcriptome
studies (Wynn et al., 2015).
Recent transcriptomic studies have also explored the
diagnostic and prognostic potential of micro-ribonucleic acids
(miRNA) in neonatal sepsis (Table 1). miRNAs are more stable
than messenger (m)RNA and increasing evidence supports their
importance in sepsis pathophysiology and potential as sepsis
markers (Wang et al., 2015; Inal et al., 2016).
Chen et al. identified 10 miRNAs significantly altered
during neonatal sepsis in preterm and term infants using
microarray, which were confirmed using quantitative real-time
reverse transcription-polymerase chain reaction (qRT-PCR). The
identified miRNAs were linked to genes and proteins involved
in pathogen recognition, inflammation, immune cell activation,
release of pro-inflammatory cytokines and apoptosis (Chen
et al., 2014). Wang et al. assessed the utility of adult sepsis
miRNA biomarkers (miR-15a/15b/16/223) using blood samples
collected during septic screens from term neonates. qRT-PCR
analysis showed only miR-15a and miR-16 was significantly up-
regulated in neonatal sepsis patients compared to controls, with
higher area under the curve (AUC) values compared to miR-
15b and miR-223. Both miR-15a and miR-16 were found to play
a pivotal role in regulating lipopolysaccharide (LPS)-induced
inflammatory responses during sepsis (Wang et al., 2015).
Separately, in LPS stimulated neonatal leukocytes derived from
cord blood of infants delivered by healthy mothers, miRNA let-
7b-5p expression was found to be significantly lower compared
to adults (Yu et al., 2016).
The mRNA and miRNA studies reviewed observed
transcriptional profile differences between infected and control
cases that were consistently linked to functions of the innate
immune system. Collectively, these studies demonstrate the
potential of microarray-based approaches to identify new gene
signatures for improved pathophysiological understanding
of neonatal sepsis. DNA microarrays, though limited by the
number of probes available, remain the most common method
to determine transcriptional expression level changes during
neonatal sepsis for both mRNA and miRNA (Skibsted et al.,
2013; Cernada et al., 2014; Chen et al., 2014; Smith et al., 2014;
Wynn et al., 2015).
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TABLE 1 | Summary of studies using transcriptomics, proteomics and metabolomics approaches.
Reference Methodology Study population and case
definitions
Type of sample Principal findings Study limitations
Smith et al., 2014 Microarray with 48,802
human gene probes
62 preterm and term neonates
(24–42 weeks gestation);
infected (n = 27) and controls
(n = 35)
Infected cases
• Confirmed positive blood
culture for Gram-negative or
Gram-positive bacteria.
• Full clinical assessment for
early and late signs and
symptoms of sepsis (e.g.,
presence of lethargy, jaundice,
temperature instability,
bradycardia and abnormal lab
parameters for white cell
count, neutrophil count and
platelets)
Controls
• Blood collected for non-clinical
reasons (e.g., screening test
for maternal thyroid disease,
bilirubin check for jaundice or
electrolyte checks)
Peripheral blood • Identified a 52-gene
immune-metabolic network
associated with sepsis
• The individual innate, adaptive and
metabolic pathway markers had
accuracy of 84, 65, and 74%,
respectively; combined use of three
pathway markers had the highest
accuracy of 98% for predicting
bacterial infections in neonates
• The robustness of the
52-gene
immune-metabolic
network for predicting
bacterial infections not
yet validated in
large-scale studies
across multiple neonatal
units
Cernada et al., 2014 Microarray with
>28,000 human gene
probes
36 VLBW infants; septic
(n = 17) and controls
(n = 19)
Septic cases
• Positive blood culture for
Gram-positive or
Gram-negative bacteria
• Presence of risk factors (e.g.,
maternal chorioamnionitis,
mothers incompletely treated
or not tested for group B
streptococcus infection and/or
exposure to indwelling devices
or surgery)
• Presence of >3 clinical signs
(e.g., temperature instability,
respiratory symptoms
including apnea or cyanosis,
tachycardia or bradycardia,
neurological symptoms
including hypotonia or lethargy
and/or gastrointestinal
symptoms including vomiting
or poor feeding)
Controls
• Blood collected from infants
without clinical signs of
infection
Peripheral blood • Genome-wide expression profiles
could discriminate between septic
infants and controls with 100%
sensitivity and 68% specificity
• Showed 554 genes were
differentially expressed between
neonates with bacterial sepsis and
matched controls, with 66 genes
associated with tumor necrosis
factor and 56 genes with cytokine
signaling
• Limited number of
patients in the study
• Authors consider study
as “starting point to
perform strongly
powered, prospective
collaborative studies in
the neonatal
population”
Wynn et al., 2015 Microarray with 20,533
human gene probes
68 preterm and term neonates
(23–42 weeks gestation; with
EOS (n = 6), LOS (n = 9), clinical
sepsis (n = 22) and uninfected
(n = 31)
Peripheral blood • Identified significant differences in
transcriptome of infants with EOS
or LOS; and showing importance of
accounting for timing of sepsis
episode when investigating
transcriptional profiles
• Limited sample size
especially for EOS and
LOS groups
• Whole blood analyses
without cell typing. This
limits examination of
cell-specific gene
expression
(Continued)
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TABLE 1 | Continued
Reference Methodology Study population and case
definitions
Type of sample Principal findings Study limitations
Sepsis (EOS/LOS) cases
• Positive blood culture for
Gram-positive or
Gram-negative bacteria
• Presence of persistent (>2
days) abnormal clinical signs
such as ill appearing and
respiratory or cardiovascular
signs
• Presence of abnormal
laboratory results showing
systemic inflammation (e.g.,
CRP >45 mg/L within 48 h of
evaluation)
Clinical sepsis cases
• Negative blood culture
• Presence of persistent (>2
days) abnormal clinical signs
such as ill appearing and
respiratory or cardiovascular
signs
• Presence of abnormal
laboratory results showing
systemic inflammation (e.g.,
CRP >45 mg/L within 48 h of
evaluation)
Uninfected cases
• Negative blood culture
• Discontinued antibiotics
treatment <48 h after initiation.
• CRP <10 mg/dL in at least
two of the serial measurement
results with 24 h apart
• Minimal mortality in
cohort limited
comparisons between
survivors and
nonsurvivors
Chen et al., 2014 miRNA microarray and
qRT-PCR
48 neonates; preterm (<37
weeks gestation, n = 5) and
term (>37 weeks gestation,
n = 43); with Gram-positive
(n = 12), Gram-negative sepsis
(n = 12) and uninfected (n = 24)
Sepsis cases
• Positive blood culture with
Gram-positive or
Gram-negative bacteria,
respectively
• Positive clinical or laboratory
screen
Uninfected cases
• Negative blood culture
• Negative clinical and
laboratory screen
Peripheral blood • Identified significant up-regulation
of miR-101/122/185 and
down-regulation of miR-
96/182/141/143/181a/29a/1184 in
infants with neonatal sepsis
• Significantly altered miRNAs
identified were involved in host
immune responses (e.g., pathogen
recognition, pro-inflammatory
cytokine release and immune cell
activation) during neonatal sepsis
• Exploratory pilot study
based on available
clinical samples with no
formal power or sample
size calculations
• Limited sample size
with no age-matched
controls
Wang et al., 2015 qRT-PCR 87 term neonates; with sepsis
(n = 46) and controls (n = 41)
Sepsis cases
• Positive blood culture with
Gram-positive or
Gram-negative bacteria,
respectively
• Positive clinical or laboratory
screen
Peripheral blood • Identified up-regulated miR-15a
and miR-16 in neonatal sepsis, with
AUC values of 0.85 and 0.86,
respectively, for neonatal sepsis
diagnosis
• The miRNAs identified
were not validated in
large-scale studies in
multiple neonatal units
(Continued)
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TABLE 1 | Continued
Reference Methodology Study population and case
definitions
Type of sample Principal findings Study limitations
Controls
• Blood collected from patients
with upper respiratory infection
or pneumonia
Yu et al., 2016 miRNA microarray and
qRT-PCR
Neonates (n = 5) and adults
(n = 5) for isolation of majority of
leukocyte subpopulations; and
neonates (n = 31) and adult
(n = 19) for isolation of pDC
Experimental design
• Human umbilical cord blood
was collected from healthy
mothers at time of elective
Cesarean section or normal
spontaneous delivery
• Cells were separated and left
unstimulated or stimulated
with stimulatory agents
including LPS
Cord blood • Identified decreased miRNA
let-7b-5p expression in cord blood
leukocytes
• Let-7b-5p miRNA inhibits
LPS-induced IL-6 and TNF-α
production in monocytes
• Neonatal leukocyte
responses were
compared to adults
instead of age-matched
controls, with a small
neonatal sample size
used particularly for
isolation of leukocyte
subpopulations
• Only specific leukocyte
populations were used
for analyses instead of
whole blood
• The leukocyte
responses were
assessed using cord
blood from neonates
born to healthy mothers
and may not be
reflective of
miRNA-mediated
regulation of immune
responses in neonates
with culture-proven
bacterial sepsis, the
population most in need
of improved sepsis
management
Kim et al., 2015 Magnetic multiplexed
nano-biosensor
platform for MMP-7
and EpCAM
20 preterm neonates (24–35
weeks gestation); with sepsis
(n = 5), NEC (n = 10) and
controls (n = 5).
Sepsis
• Positive blood culture
• Absence of uniform serum
CRP elevation
NEC
• Pneumatosis intestinale in
pathognomonic abdominal
radiographic result
Controls
• Absence of sepsis and NEC
Peripheral blood
plasma
• MMp7/EpCAM ratio has high
diagnostic accuracy for
differentiating infants with NEC or
sepsis from control infants with
AUC values of 1.00 and 0.96
respectively
• Pilot study with small
sample size and
no power analysis
performed
• Authors concede that
controls may yield
some false negatives for
sepsis or NEC
• The biosensor platform
not yet validated in
large-scale multicenter
studies
Ng et al., 2010 MALDI-TOF MS and
protein chip arrays
Biomarker discovery cohort
74 very preterm neonates
(<32 weeks gestation), with
sepsis/NEC (n = 37) or
non-sepsis (n = 37)
Case-control validation
cohort 80 neonates; with
sepsis/NEC (n = 40) and
non-sepsis (n = 40)
Prospective validation cohort
104 preterm neonates (<35
weeks gestation); with
sepsis/NEC (n = 42), probable
clinical sepsis (n = 13) and
non-sepsis (n = 49)
Peripheral blood
plasma
• ApoSAA score capable of
differentiating infants with sepsis
and NEC from control infants
Case-control validation cohort
• ApoSAA score showed highest
diagnostic performance for infants
with sepsis and NEC at a 0.75
cut-off value; with 90% sensitivity
and 95% specificity
Prospective validation cohort
• ApoSAA score at 0.75 cut-off value
showed 84% specificity and 89%
sensitivity
• Mix of bacterial and
fungal infections
precludes comparisons
with studies containing
only bacterial sepsis
• The algorithm not yet
evaluated in large-scale
multicenter bacterial
sepsis studies
(Continued)
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TABLE 1 | Continued
Reference Methodology Study population and case
definitions
Type of sample Principal findings Study limitations
Sepsis cases
• Positive blood culture for
bacterial or fungal infection
NEC cases
• Stage II or above in Bell’s
classification
Non-sepsis cases
• Negative blood culture with
definitive diagnosis unrelated
to sepsis/NEC
Probable clinical sepsis
• Negative blood culture
• Presenting >3 clinical signs
and symptoms
• Evidence of hematologic or
metabolic derangement
• Strong circumstantial
background of sepsis based
on clinical course and
laboratory results
Buhimschi et al., 2011 Discovery phase
Two-dimensional gel
electrophoresis
and MS
Validation phase
Immunoassay,
western blotting and
latent-class analysis
180 preterm neonates (<37
weeks gestation) total for
discovery and validation phases
Discovery phase
6 neonates; with clinical EOS
(n = 3) and gestational
age-matched control (n = 3)
Clinical EOS cases
• Positive blood culture
• Cord blood IL-6 > 90pg/mL
• Histological chorioamnionitis
stages II (chorionic
inflammation) or III
(full-thickness inflammation of
both amnion and chorion)
Controls
• Negative blood culture
• Cord blood IL-6 < 9 pg/mL
• No histological
chorioamnionitis
Validation phase 174
neonates; with clinical EOS
(n = 45) and no clinical EOS
(n = 129).
Clinical EOS
• Positive blood culture
and/or positive hematological
indices (≥2 of following:
absolute neutrophil count of
<7,500 or >14,500
cells/mm3; absolute band
count >1,500 cells/mm3;
immature/total neutrophil (I:T)
ratio >0.16; platelet count
<150,000 cells/mm)
No clinical EOS
• Negative blood culture
• Negative hematological indices
Cord blood serum Discovery phase
• Identified 19 proteins involved in
immunity and defense,
protease/extracellular matrix, and
transfer/carrier pathways
Validation phase
• Hp & HpRP significantly increased
in EOS
• Need to be validated in
a large-scale
multicenter cohort to
ensure Hp & HpRP can
be used across different
neonatal units to
improve EOS diagnosis
(Continued)
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TABLE 1 | Continued
Reference Methodology Study population and case
definitions
Type of sample Principal findings Study limitations
Mickiewicz et al., 2013 NMR Spectroscopy 140 patients; of which neonates
(n = 7), infants (n = 47), toddlers
(n = 54) and school age children
(n = 32) had either septic shock
(n = 60), SIRS (n = 40) or were
healthy controls (n = 40)
Septic shock
• PRISM III-APS score with
median of 3.5 (3.25–3.75)
• Median PCT of 1.7 ng/mL
SIRS
• PRISM III-APS score with
median of 24 (12–27).
• Median PCT of 3.3 ng/mL
Healthy controls
• Exclusion criteria used: any
acute illness, recent use of
anti-inflammatory medicine
(within 2 weeks), a recent
febrile illness (within 2 weeks)
or any history of acute or
chronic disease associated
with inflammation
Peripheral blood
serum
• Identified increased levels of
lactate, glucose, creatinine,
2-oxoisocaproate,
2-hydroxyisovalerate and
2-hydroxybutyrate; and decreased
threonine, acetate,
2-aminobutyrate and adipate in
sepsis
• Identified increased levels of
glucose, 2-hydroxybutyrate and
glycerol; and decreased threonine,
taurine, suberate, serine, pyruvate,
ornithine, methionine, lactate,
isoleucine, hypoxanthine, glycine,
glutamate, alanine, and adipic acid
in septic shock
• Small sample size of
neonates, with no age-
matched controls
• Mixed case definition for
septic shock consisting
of Gram-positive,
Gram-negative and
polymicrobial infection
• The metabolites
identified need to be
validated in large-scale
multicenter study
consisting of “a larger
cohort of critical ill
patients”
Fanos et al., 2014 GC-MS and NMR 25 neonates (<35 weeks mean
gestation); with sepsis (n = 9)
and healthy controls (n = 16)
Sepsis
• Received diagnosis of sepsis
Healthy controls
• Not diagnosed with sepsis and
considered healthy
Urine • Identified increased concentrations
of glucose, lactate and acetate;
and decreased ribitol, ribonic acid,
pseudouridine,
2,3,4-trihydroxybutanoic acid and
3,4,5-trihydroxypentanoic acid in
sepsis
• No criteria listed for case
definitions
• Small sample size with
no power analysis
conducted
• Identified biomarkers
not yet validated in
large-scale multicenter
studies
Apo, Apolipoprotein; AUC, area under the curve; CRP, C-reactive protein; EOS, early-onset sepsis; EpCam, epithelial cell adhesion molecule; GC-MS, gas-chromatography mass-
spectrometry; Hp, haptoglobin; HpRP, haptoglobin-related protein; IL, interleukin; LOS, late-onset sepsis; LPS, lipopolysaccharide; MALDI-TOF, matrix assisted laser desorption
ionization time of flight; miRNA, micro-ribonucleic acid; MMP, matrix metalloproteinase; MS, mass spectrometry; NEC, necrotizing enterocolitis; NMR, nuclear magnetic resonance;
pDC, plasmocytoid dendritic cell; PRISM III-APS, pediatric risk of mortality III-acute physiology; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; SAA, serum
amyloid A; SIRS, systemic inflammatory response syndrome; TNF, tumor necrosis factor; VLBW, very low birth weight.
RNA-Seq is emerging as a powerful tool for transcriptome-
wide profiling that is independent of pre-identified probe
sequences, thus allowing discovery of novel gene transcripts
to generate sepsis-related gene signatures (Chaussabel et al.,
2010). Although there have been no published studies using
RNA-Seq to identify transcriptional signatures for diagnosis
of neonatal sepsis to date, the method has shown potential
in adult studies. Pena et al. found that adult sepsis was
associated with an endotoxin tolerance signature that was useful
in differentiating true from suspected sepsis prior to clinical
sepsis confirmation and organ dysfunction prognosis (Pena
et al., 2014). RNA-Seq allows for hypothesis-free assessment of
the transcriptome for unbiased discovery-based identification
of gene signatures associated with neonatal sepsis. Presently,
the feasibility of translating NGS-based approaches into bedside
tools for neonatal sepsis remains unknown. The challenges faced
are both downstream, where extensive sample processing is
required for nucleic acid extraction and library preparation for
sequencing; and upstream, data storage (up to 150GB per whole-
genome sequencing experiment).
RNA-Seq also involves computationally intensive analysis
pipelines requiring specialized bioinformatics skills. One possible
solution to this is to reduce the dimensionality of the data
obtained from patients, focusing only on the minimal identified
gene signature required for adequate diagnostic performance
(Costa, 2014; Pena et al., 2014; Smith et al., 2014; Tebani
et al., 2016b). Such genes could be detected using more rapid
approaches such as nanostring and qRT-PCR. Nanostring allows
detection of up to 800 different transcripts in a single reaction
and is not influenced by pipetting errors, nonspecific enzymatic
reactions or reference gene instability, enabling more accurate
measurements of gene expression. However, it is limited by the
time involved from sample collection to quantitation (16–48 h)
compared to qRT-PCR (within 2 h). qRT-PCR has been routinely
used for validation of gene expression in microarray and NGS-
based sepsis studies, showing promise for clinical translation in
childhood leukemia studies and possibility of using a minimal
identified gene signature for neonatal sepsis diagnosis in the
clinical setting. This approach provides a cost-efficient, rapid, less
computationally and bioinformatically intensive alternative to
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measure gene signature expression for neonatal sepsis diagnosis
(Hoffmann et al., 2006; Chaussabel et al., 2010; Chen et al., 2014;
Tsang et al., 2017).
Proteomics of Sepsis Samples
Overall, no single protein biomarker has emerged with sufficient
sensitivity, specificity and reproducibility to accurately diagnose
sepsis. This has prompted the need to move from single protein
markers, such as CRP or procalcitonin, to the use of panels
of biomarkers to improve diagnostic performance (Ludwig and
Hummon, 2017). Proteomic studies on body-fluids and tissues in
both human adults and animal models assessing the mechanism
of both adult and neonatal sepsis have previously been reviewed
(Cao and Robinson, 2014; Delanghe and Speeckaert, 2015). This
section focuses on recent proteomic studies aimed at identifying
biomarkers for human neonatal sepsis.
Necrotizing enterocolitis (NEC) shares similar manifestations
with neonatal sepsis, including increased CRP levels, making it
difficult to distinguish from sepsis. Several proteins have been
identified as potential candidates to differentiate both sepsis
and/or NEC from uninfected neonates (Table 1). Kim et al.
employed a multiplexed nano-biosensor proteomic platform
on plasma samples from 20 preterm neonates to formulate
a ratio of protein levels based on matrix metalloproteinase
(MMP)-7 and epithelial cell adhesion molecule (EpCAM)
concentrations. The MMP-7/EpCAM ratio differentiated NEC
from sepsis and healthy controls with high diagnostic accuracy,
although the study was limited by a small sample size and
lack of information on how neonates were diagnosed for sepsis
(Kim et al., 2015). Ng et al. assessed plasma samples from
preterm infants with or without NEC/sepsis using ProteinChip
array and matrix assisted laser desorption ionization-time of
flight (MALDI-TOF) mass spectrometry (MS). The protein
concentrations identified from diagnostic proteomic peaks were
measured by immunoassay. Multivariate logistic regression
analysis determinedApolipoprotein (Apo)C2 and serum amyloid
A (SAA) as the most promising markers based on immunoassay
concentrations, and were used to construct an ApoSAA score
that was capable of differentiating sepsis/NEC cases from non-
sepsis/NEC cases. Downstream validation in separate case-
control and prospective cohort studies of preterm infants showed
high diagnostic performance. Further confirmation in large
multicenter trials will be necessary before the ApoSAA score can
be translated for use to diagnosis sepsis/NEC cases (Ng et al.,
2010). Separately, Buhimschi et al. profiled the serum proteome
from venous cord blood of preterm neonates with and without
EOS. Gel and MS-based proteomics identified 19 proteins with
differential abundance between cases and controls. Downstream
validation involving neonates with and without EOS showed
that Haptoglobin (Hp) and Haptoglobin-related protein (HpRP)
immunoreactivity were significantly elevated in both clinical and
culture-confirmed EOS neonates, and that a combination of Hp
& HpRP, IL-6 and neonatal hematological indices could improve
the clinical EOS diagnosis (Buhimschi et al., 2011).
Together, these proteomic studies highlight the potential
to use a panel of biomarkers for more effective diagnosis.
Importantly, the use of MS-based technologies for proteomic
profiling in these studies underscore the capacity to discover
new protein biomarker combinations through a hypothesis-free
unbiased approach (Ng et al., 2010; Buhimschi et al., 2011).
Compared to traditional hypothesis-driven approaches, where
proteins are pre-selected for analysis, MS-based omics can
screen thousands of protein abundances and post-translational
modifications in a single acquisition, allowing unprecedentedly
wide coverage for discovery of novel biomarkers for panel
construction. Proteomic biomarkers identified through this
approach have potential to be translated into use on bench-top
mass spectrometers with optimized and validated assays that
are ready for clinical use, allowing timely analysis of multiple
proteins in very low abundances close to the bedside (Honour,
2003; Rifai et al., 2006; Ludwig and Hummon, 2017). However,
translating a MS-based approach for diagnosis of neonatal sepsis
in the clinic has not been assessed. Instrumentation costs will
need to be reduced and a standardized protocol for sample
collection, preparation, processing, analysis and reporting that
is not time-intensive (<12 h) needs to be developed before MS-
based technologies can be feasibly utilized by the bedside (Tebani
et al., 2016a). Multiplex immunoassays can be developed from
identified multi-biomarker panels and performed using available
technologies such as Luminex
TM
. A point-of-care protein-
microarray device for quantification of multiple serum proteins
using minimal sample volume from neonates has previously
been developed, supporting potential to translate validatedmulti-
protein biomarker panels for bedside diagnosis (Buchegger et al.,
2012; Tighe et al., 2015).
Metabolic Phenotyping of Septic Infants
Sepsis induces hypoxia, oxidative stress, and an increased
demand for energy resulting in both glucose metabolism
and oxidative metabolism of fatty acids; necessitating the
monitoring of metabolome dysregulations during neonatal
sepsis. Metabolomics can characterize thousands of intermediate
to low molecular-weight carbohydrates, amino acids, lipids and
other molecules generated by the interaction between host
genome, the gut microbiome and environment. It is thus a
useful tool to investigate metabolic perturbations related to
neonatal sepsis for identification of novel biomarkers. The
mainstream analytical technologies for metabolic profiling are
nuclear magnetic resonance (NMR) and MS connected to
capillary electrophoresis, gas chromatography (GC) or liquid
chromatography (LC) separation methods. Whilst NMR enjoys
relatively fast and straightforward metabolite annotation and
preservation of samples, MS is more sensitive and can detect
metabolites with lower abundance. Clinical and pharmaceutical
applications of metabolomics in newborns and infants has been
reviewed previously (Sumner et al., 2007; Antonucci et al., 2012;
Dessì et al., 2014; Fanos et al., 2014). This section focuses on
metabolomic studies in neonatal sepsis (Table 1).
Mickiewicz et al. usedH-NMR analysis of serum samples from
a mixed pediatric cohort consisting of neonates and children up
to 11 years of age. Several metabolites, including lactate, glucose,
adipate, 2-hydroxybutyrate and threonine were differentially
regulated between septic and non-septic patients across age
groups, and also distinguished those with systemic inflammatory
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response syndrome (SIRS). The outcome models designed using
orthogonal partial least square discriminant analysis (OPLS-DA)
was predictive of mortality in pediatric patients with septic shock
(Mickiewicz et al., 2013). Fanos et al. profiled the metabolome
of non-invasively collected urine samples from preterm septic
newborns and healthy controls using H-NMR and GC-MS, and
found increased concentrations of several metabolites including
glucose and lactate but decreased concentrations of metabolites
including ribitol, pseudouridine and 2-ketogluconic acid. Urine
samples from sepsis patients also had differential levels of
acetone ketone bodies, likely due to the hypermetabolic responses
occurring during sepsis. Interestingly, OPLS-DA of the samples
showed clear separation of control and sepsis samples, with
ability to discriminate EOS from LOS (Fanos et al., 2014).
Overall, despite different sample types used, both
metabolomic studies consistently found increased levels
of glucose and lactate in septic patients. The inclusion of both
metabolites with other biomarkers such as ribitol, pseudouridine,
adipate, 2-hydroxybutyrate and threonine suggests potential to
develop a panel of stable early predictors for neonatal sepsis.
These studies demonstrate the ability to conduct hypothesis-
free screening of the metabolome using metabolomics-based
technologies (NMR and MS) to discover novel compositions
of metabolites for neonatal sepsis diagnosis (Mickiewicz et al.,
2013; Fanos et al., 2014). In particular, coupling of MS analyzers
with different separation methods (GC or LC) for acquisitions
could improve sensitivity, specificity, chemical coverage and
dynamic range for untargeted metabolite discovery from
various biological samples (May and McLean, 2016; Tebani
et al., 2016b). With clear evidence of metabolic disturbances
caused by sepsis or infection, metabolites possess high potential
to serve as biomarkers or predictors for sepsis and infection
during the neonatal period. Currently, only a limited number
of small-scale studies have been carried out, and translation of
identified metabolite biomarker panels for bedside diagnosis
of neonatal sepsis remains unknown (Mickiewicz et al., 2013;
Fanos et al., 2014). MS-based analyses remain time intensive
and costly, requiring extensive sample processing in addition to
specialized hardware and software for spectral data acquisition,
preprocessing and data analysis. Despite this, MS-based
technologies have routinely been used for screening of inborn
errors of metabolism in newborns with commercial companies
working to develop metabolite-based biomarker diagnostic tests,
paving the way for future translation of a quick and accurate
metabolite-based biomarker test for neonatal sepsis diagnosis
(Nagana Gowda and Raftery, 2013; Tebani et al., 2016b).
Toward Precision Medicine for Neonatal
Sepsis
Despite limited research in the field of neonatal sepsis to
date and limitations within each study (Table 1), available data
highlights potential of omics-based approaches to interrogate
sepsis pathophysiology for the discovery of novel biomarkers
and diagnostic signatures for sepsis. Investigating a septic
event at multiple levels, such as across the transcriptional
and metabolic response, and at different times during sepsis
should capture novel features that account for interactions
between genes and biomolecules in a systems network. This
can also identify the dynamic changes between networks of
genes and biomolecules from different systems, facilitating
the discovery of novel dynamical network biomarkers for
neonatal sepsis. Identification of dynamical network biomarkers,
unlike traditional markers such as the use of a single
protein concentration, may allow precise stratification of
patients by disease phenotype (such as severity), thereby
allowing better prognosis and targeted use of therapeutics
(Christaki and Giamarellos-Bourboulis, 2014; Li and Chen,
2014).
The shift from empirical evidence-based medicine to
stratified, omics-led medicine for neonatal sepsis remains in
its infancy and faces several challenges (Figure 1). Firstly,
neonatal sepsis is a heterogeneous clinical syndrome without
a consensus definition, therefore available studies have used
differing case definitions (Table 1). Multiple factors contribute
to heterogeneity of disease, including the specific pathogen
involved (type, load and site of invasion) and the maturational
state and capacity of the host immune system (influenced by
gestational and postnatal age and associated comorbidities). The
inability to stratify patients by disease state based on a clear and
consistent definition hinders our ability to compare findings
between studies, impeding progress of validating identified
biomarkers or gene signatures that can universally improve
diagnostic and prognostic tests for neonatal sepsis (Chen et al.,
2014; Wynn, 2016). Secondly, we lack representative animal
models to investigate and validate neonatal sepsis biomarkers
and investigate the dynamics of sepsis pathophysiology. Thirdly,
novel biomarkers discovered will need to be selected from
an appropriate biological sample that can be pragmatically
translated for clinical use (Thongboonkerd, 2013). Given the
limited number of studies that have identified biomarkers
capable of translating into a bench-side test for neonatal sepsis,
analyzing a wide range of longitudinal samples, including
whole blood, plasma, serum and urine would be the most
comprehensive way of finding novel biomarkers and diagnostic
gene signatures (Willis and Lord, 2015). The robustness of the
identified markers will need to be validated in appropriately
powered multicenter studies to account for instrumental,
technical, biological and physiological variations. Finally,
whilst our ability to generate omics-based data for neonatal
sepsis has significantly improved in the last 10 years with
the reducing cost and increasing speed of high-throughput
technologies, it has led to a bottleneck with data analysis and
interpretation.
Theoretically, discovery of biomarkers and/or sepsis
signatures through integration of multi-omic data has potential
to stratify neonates with sepsis for improved treatment and
prognosis. However, despite increasing access to multi-omics
profiles, our ability to analyze and interpret high-dimensional
data remains limited by our understanding of the complex
interactions between the genome, transcriptome, proteome
and metabolome. The complexity of sepsis pathophysiology,
heterogenic nature of clinical data, along with bioinformatical
and statistical limitations hinder our ability to integrate
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FIGURE 1 | Summary of current and future approaches for diagnosis of neonatal sepsis.
multi-omic data for interpretation of relationships between
“networks” and “networks of networks” (Vucic et al., 2012;
Li and Chen, 2014; Alyass et al., 2015). Data storage and
management solutions that can integrate each patient’s clinical
records, laboratory results and omics data need to be developed
and implemented before we can transition into precision
medicine by the bedside. These solutions will need to be robust
enough to deal with the gigabytes of multiple omic platform-
specific data, from a range of biological sample types, and across
varying instrumental technologies (Gullapalli et al., 2012; Tebani
et al., 2016b).
As we move from stratified medicine into the era of precision
medicine, the gap between biological science and medicine needs
to be bridged in order to translate a patient-specific bedside test
for neonatal sepsis. This will require open collaborations and
knowledge sharing across multiple disciplines from laboratory
scientists to statisticians, computational biologists and clinicians.
Further, the translation will require investment into informatics
infrastructures that can meet the computationally intensive
pipelines for integrative multi-omics, clinical and laboratory data
analytics and visualization (Figure 1). Additionally, the legal and
ethical framework ensuring confidentiality and privacy of patient
information will need to be established. The storage and secure
sharing of data through cloud computing solutions will also need
to be addressed in order to provide informative digital health
reports that guide clinicians for personalized management of
sepsis in neonates (Costa, 2014; Alyass et al., 2015; Willis and
Lord, 2015; Tebani et al., 2016b).
The use of precision medicine is highly relevant for
neonatology. The heterogeneous nature of neonatal sepsis means
that our current approaches to diagnosis are too simplistic
and imprecise to identify affected individuals accurately (Wynn,
2016). The nature of neonatal medicine, with its highly intensive
and frequent monitoring of infants, often over protracted periods
and from birth, makes it ideal for translation to the precision
medicine setting. Neonatal precision medicine will allow a more
predictive and preventive approach, where septic infants can
be identified ahead of clinical disease phenotype expression,
ensuring prompt and effective antibiotic use. Ultimately, the
era of precision medicine for neonatal sepsis, built on the
platforms of omics technologies, holds promising potential to
ensure quicker andmore accurate diagnosis of neonatal sepsis for
personalized treatment and improve prognosis of septic neonates
(Thongboonkerd, 2013; Christaki and Giamarellos-Bourboulis,
2014).
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